Showing results (201-210 of 290) with videos related to
Sort By:
Pageof 29
The Oncologist|March 16, 2018
Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care TestingJames H Suh, Alexa B Schrock, Adrienne Johnson, et al.Oncotarget|May 10, 2014
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigmsJennifer J Wheler, Barbara A Parker, Jack J Lee, et al.Nature Genetics|November 22, 2016
Inactivation of Capicua drives cancer metastasisRoss A Okimoto, Frank Breitenbuecher, Victor R Olivas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancerRoy S Herbst, Angela M Davies, Ronald B Natale, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2019
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor TherapyTodd C Knepper, Meagan Montesion, Jeffery S Russell, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2012
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancerM Catherine Pietanza, Shirish M Gadgeel, Afshin Dowlati, et al.The Oncologist|May 2, 2019
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for TherapyAparna R Parikh, Yuting He, Ted S Hong, et al.Gastroenterology|March 6, 2019
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as BiomarkersAatur D Singhi, Ben George, Joel R Greenbowe, et al.Oncotarget|April 21, 2017
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomasRoman Groisberg, David S Hong, Vijaykumar Holla, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 27, 2013
Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapyJeffrey S Ross, Kai Wang, Rami N Al-Rohil, et al.Pageof 29